Study on the Registration of Coronary Heart Disease Patients Undergoing PCI

• Status: Completed
• Trial end date: 2018-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Study on the registration of coronary heart disease patients undergoing PCI in Chinese's population. Get the incidence of adverse events in these patients after PCI, a clear type of adverse reaction, forms, influencing factors, to establish risk management processes, clinical safety and reasonable treatment, and provide the basis for further research and reference.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Third Xiangya Hospital of Central South University
• Treatments: Clopidogrel; Platelet Aggregation Inhibitors; Ticagrelor

Criteria

Inclusion Criteria:

• Chinese's patients diagnosed with coronary heart disease and accept stent implantation.

• Accept aspirin and P2Y12 receptor inhibitors (clopidogrel or ticagrelorwere）after stent implantation.

• Willingness and ability to sign informed consent.

• Can communicate effectively and complete the trial.

Exclusion Criteria:

• Occurrence of a major complication during the procedure of percutaneous coronary intervention or before platelet function testing.

• Allergy or intolerance to aspirin or P2Y12 receptor inhibitors (Clopidogrel or Ticagrelor）